Issue

Vol. 66 No. 2: Issue 2

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Microarray analysis of preterm preeclampsia

https://doi.org/10.14715/cmb/2020.66.2.9
Huina Liu
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Junjie Yu
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Wenjing Yuan
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Huirong Shi
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Wenli Guan
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China

Corresponding Author(s) : Huina Liu

liuhuina6@126.com

Cellular and Molecular Biology, Vol. 66 No. 2: Issue 2

Abstract

Premature preeclampsia is the second cause of maternal mortalities around the world. To investigate its potential driving mechanism(s), we constructed a multi-regulatory-mediated preeclampsia dysfunction module. Through combining differential expression analysis, co-expression analysis, and enrichment analysis, we obtained 23 sets of preeclampsia expression disorder modules in the disease, which involve the modular aggregations of 3016 genes. The modules were subjected to be analyzed for GO and KEGG paths for enrichment analysis. Based on these pivotal regulators, it is possible to manipulate the essential parts of the modular subnetwork and study their cooperative acts to mediate the driving mechanism of the preeclampsia. Simultaneously, they mainly cause the onset of the disease through the regulation of the apoptotic signaling pathway, down-regulation of an inflammatory response and retinol metabolism. This may present a potential driving mechanism for the disease. The predictor analysis of the regulators showed a series of non-coding RNAs that have potentially significant regulatory effects on the disease, including miR-182-5p, miR-200b-3p, miR-23a-3p, miR -429, miR-590-3p, and transcription factors. These pivotal regulators might mediate the potential driving processes. Based on a comprehensive multivariate analysis, we found a possible driving mechanism in which significant pivotal regulators were used as distinct functional segments in the preterm preeclampsia-driven process.

Keywords

Early preeclampsia Imbalance module Pivot regulator Module subnetwork Drive process
Liu, H., Yu, J., Yuan, W., Shi, H., & Guan, W. (2020). Microarray analysis of preterm preeclampsia. Cellular and Molecular Biology, 66(2), 59–64. https://doi.org/10.14715/cmb/2020.66.2.9
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Henderson JT, Thompson JH, Burda BU, Cantor A. Preeclampsia Screening: Evidence Report and Systematic Review for the US Pre¬ventive Services Task Force. JAMA 2017; 317: 1668-1683.
  2. Rasmussen S, Ebbing C, Irgens LM. Predicting preeclampsia from a history of preterm birth. PloS One 2017; 12: e0181016.
  3. Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines. Clin J Am Soc Nephrol 2016; 11: 1102-1113.
  4. Sasser JM, Murphy SR, Granger JP. Emerging drugs for pree¬clampsia--the endothelium as a target. Expert Opin Emerg Drugs 2015; 20: 527-530.
  5. Amaral LM, Wallace K, Owens M, LaMarca B. Pathophysiology and Current Clinical Management of Preeclampsia. Curr Hypertens Rep 2017; 19: 61-66.
  6. Dong X, Gou W, Li C, Wu M, Han Z, Li X, Chen Q. Proteinu¬ria in preeclampsia: Not essential to diagnosis but related to disease severity and fetal outcomes. Pregnancy Hypertens 2017; 8: 60-64.
  7. Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. Lancet 2016; 387: 999-1011.
  8. Sibai BM, Stella CL. Diagnosis and management of atypical pree¬clampsia-eclampsia. Am J Obstet Gynecol 2009; 200: 481 e1-e7.
  9. Boyle VT, Thorstensen EB, Mourath D, Jones MB, McCowan LM, Kenny LC, Baker PN. The relationship between 25-hydroxyvi¬tamin D concentration in early pregnancy and pregnancy outcomes in a large, prospective cohort. Br J Nutr 2016; 116: 1409-1415.
  10. Wei SQ. Vitamin D and pregnancy outcomes. Curr Opin Obstet Gynecol 2014; 26: 438-447.
  11. van Vliet EO, Askie LA, Mol BW, Oudijk MA. Antiplatelet Agents and the Prevention of Spontaneous Preterm Birth: A Syste¬matic Review and Meta-analysis. Obstet Gynecol 2017; 129: 327- 336.
  12. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116: 402-414.
  13. Putra RA, Effendi JS, Permadi W, Bandiara R, Fauziah PN. Role of statin as inducer of Hmox-1 system in treatment of preeclampsia. Cell Mol Biol (Noisy-le-grand) 2018; 64: 1-4.
  14. Committee Opinion No. 638: First-Trimester Risk Assessment for Early-Onset Preeclampsia. Obstet Gynecol 2015; 126: e25-27.
  15. Cui L, Shu C, Liu Z, Tong W, Cui M, Wei C, Tang JJ, Liu X, Hai H, Jiang J, He J, Zhang DY, Ye F, Li Y.The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia. Pregnancy Hypertens 2018; 13: 127-132.
  16. Bellos I, Fitrou G, Pergialiotis V, Papantoniou N, Daskalakis G. Mean platelet volume values in preeclampsia: A systematic review and meta-analysis. Pregnancy Hypertens 2018; 13: 174-180.
  17. Chen X, Xu Y, Meng L, Chen X, Yuan L, Cai Q, Shi W and Huang G: Non-parametric partial least squares–discriminant analy-sis model based on sum of ranking difference algorithm for tea grade identification using electronic tongue data identify tea grade using e-tongue data. Sens Actuators B Chem 127924, 2020.
  18. Nie Y, Luo F and Lin Q: Dietary nutrition and gut microflora: A promising target for treating diseases. Trends Food Sci Technol 75: 72-80, 2018.
  19. Ren Y, Jiao X and Zhang L: Expression level of fibroblast growth factor 5 (FGF5) in the peripheral blood of primary hypertension and its clinical significance. Saudi J Biol Sci 25(3): 469-473, 2018.
  20. Liang Y, Lin Q, Huang P, Wang Y, Li J, Zhang L and Cao J: Rice Bioactive Peptide Binding with TLR4 To Overcome H2O2-Induced Injury in Human Umbilical Vein Endothelial Cells through NF-κB Signaling. J Agri Food Chem 66(2): 440-448, 2018.
  21. Wang L, Lin Q, Yang T, Liang Y, Nie Y, Luo Y and Luo F: Oryza¬nol modifies high fat diet-induced obesity, liver gene expression pro¬file, and inflammation response in mice. J Agri Food Chem 65(38): 8374-8385, 2017.
  22. Lou Y, Shi J, Guo D, Qureshi AK and Song L: Function of PD-L1 in antitumor immunity of glioma cells. Saudi J Boil Sci 24(4): 803-807, 2017.
  23. Guo T, Lin Q, Li X, Nie Y, Wang L, Shi L and Luo F: Octacosa¬nol attenuates inflammation in both RAW264. 7 macrophages and a mouse model of colitis. J Agri Food Chem 65(18): 3647-3658, 2017.
  24. Li W, Jia MX, Wang JH, Lu JL, Deng J, Tang JX and Liu C: As¬sociation of MMP9-1562C/T and MMP13-77A/G polymorphisms with non-small cell lung cancer in southern Chinese population. Biomol 9(3): 107-119, 2019.
  25. Nie Y, Luo F, Wang L, Yang T, Shi L, Li X, Shen J, Xu W, Guo T and Lin Q: Anti-hyperlipidemic effect of rice bran polysaccharide and its potential mechanism in high-fat diet mice. Food Func 8(11): 4028-4041, 2017.
  26. Lou Y, Yang J, Wang L, Chen X, Xin X and Liu Y: The clini¬cal efficacy study of treatment to Chiari malformation type I with syringomyelia under the minimally invasive surgery of resection of Submeningeal cerebellar Tonsillar Herniation and reconstruction of Cisterna magna. Saudi J Biol Sci 26(8): 1927-1931, 2019.
  27. Lou Y, Guo D, Zhang H and Song L: Effectiveness of mesenchy¬mal stems cells cultured by hanging drop vs. conventional culturing on the repair of hypoxic-ischemic-damaged mouse brains, measured by stemness gene expression. Open Life Sci 11(1): 519-523, 2016.
  28. Nahum Sacks K, Friger M, Shoham-Vardi I, Spiegel E, Sergien¬ko R, Landau D, Sheiner E. Prenatal exposure to preeclampsia as an independent risk factor for long-term cardiovascular morbidity of the offspring. Pregnancy Hypertens 2018; 13: 181-186.
  29. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010; 376: 631-644.
  30. Konecna B, Vlkova B, Celec P. Role of fetal DNA in preeclamp¬sia (review). Int J Mol Med 2015; 35: 299-304.
  31. Chaiworapongsa T, Chaemsaithong P, Korzeniewski SJ, Yeo L, Romero R. Pre-eclampsia part 2: prediction, prevention and mana¬gement. Nat Rev Nephrol 2014; 10: 531-540.
  32. Law KP, Han TL, Tong C, Baker PN. Mass spectrometry-based proteomics for pre-eclampsia and preterm birth. Int J Mol Sci 2015; 16: 10952-10985.
  33. Mendola P, Ghassabian A, Mills JL, Zhang C, Tsai MY, Liu A, Yeung EH. Retinol-Binding Protein 4 and Lipids Prospectively Measured During Early to Mid-Pregnancy in Relation to Preeclamp¬sia and Preterm Birth Risk. Am J Hypertens 2017; 30: 569-576.
  34. Tokumura A, Kume T, Taira S, Yasuda K, Kanzaki H. Altered ac¬tivity of lysophospholipase D, which produces bioactive lysophos¬phatidic acid and choline, in serum from women with pathological pregnancy. Mol Hum Reprod 2009; 15: 301-310.
  35. Abdel Razik M, El-Berry S, Abosereah M, Edris Y, Sharafeldeen A. Prophylactic treatment for preeclampsia in high-risk teenage pri¬migravidae with nitric oxide donors: a pilot study. J Matern Fetal Neonatal Med 2016; 29: 2617-2620.
  36. McCarthy C, Kenny LC. Therapeutically targeting mitochondrial redox signalling alleviates endothelial dysfunction in preeclampsia. Sci Rep 2016; 6: 32683.
  37. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365: 785-799.
  38. Xu Z, Zhao F, Lin F, Xiang H, Wang N, Ye D, Huang Y. Pree¬clampsia is associated with a deficiency of lipoxin A4, an endoge¬nous anti-inflammatory mediator. Fertil Steril 2014; 102: 282-290.
  39. Blaya D, Coll M, Rodrigo-Torres D, Vila-Casadesus M, Altami¬rano J, Llopis M, Graupera I, Perea L, Aguilar-Bravo B, Dí­az A, M Banales J, Joan Clí ria J, Lozano JJ, Bataller R, Caballerí­a J, Ginès P, Sancho-Bru P.Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. Gut 2016; 65: 1535-1545.
  40. Sinha M, Ghatak S, Roy S, Sen CK. microRNA-200b as a Swit¬ch for Inducible Adult Angiogenesis. Antioxid Redox Signal 2015; 22: 1257-1272.
  41. Lledo B, Llacer J, Ortiz JA, Martinez B, Morales R, Bernabeu R. A pharmacogenetic approach to improve low ovarian response: The role of CAG repeats length in the androgen receptor gene. Eur J Obstet Gynecol Reprod Biol 2018; 227: 41-45.
  42. Maaliki D, Issa K, Al Shehabi T, El-Yazbi A, Eid AH. The role of alpha2-adrenergic receptors in hypertensive preeclampsia: A hy¬pothesis. Microcirculation 2019; 26: e12511.
  43. Motawea HKB, Chotani MA, Ali M, Ackerman W, Zhao G, Ahmed AAE, Buhimschi CS, Buhimschi IA. Human Placenta Ex¬presses alpha2-Adrenergic Receptors and May Be Implicated in Pathogenesis of Preeclampsia and Fetal Growth Restriction. Am J Pathol 2018; 188: 2774-2785.
  44. Li L, Hou A, Gao X, Zhang J, Zhang L, Wang J, Li H, Song Y. Lentivirus-mediated miR-23a overexpression induces trophoblast cell apoptosis through inhibiting X-linked inhibitor of apoptosis. Biomed Pharmacother 2017; 94: 412-417.
  45. Wu J, Tao Y, Shang A, Wang W, Zhang Y, Hu L, Wang J, Wang Y, Guo N. Effect of the interaction between MiR-200b-3p and DNM¬T3A on cartilage cells of osteoarthritis patients. J Cell Mol Med 2017; 21: 2308-2316.
  46. Qin SB, Peng DY, Lu JM, Ke ZP. MiR-182-5p inhibited oxi¬dative stress and apoptosis triggered by oxidized low-density lipo¬protein via targeting toll-like receptor 4. J Cell Physiol 2018; 233: 6630-6637.
  47. Deng Y, Luan F, Zeng L, Zhang Y, Ma K. MiR-429 suppresses the progression and metastasis of osteosarcoma by targeting ZEB1. EXCLI J 2017; 16: 618-627.
  48. Ge X, Gong L. MiR-590-3p suppresses hepatocellular carcino¬ma growth by targeting TEAD1. Tumour Biol 2017; 39: 1-8.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 949 Download : 398